PEAK6 Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

PEAK6 Investments’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,500	Closed	-$32.4K	–	4017
2023 Q2	$32.4K	Buy	+1,500	New	+$40.5K	﹤0.01%	3517
2022 Q3	–	Sell	-1,500	Closed	-$37.4K	–	4892
2022 Q2	$32.4K	Buy	+1,500	New	+$17.8K	﹤0.01%	5642

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PEAK6 Investments's AMLX Position: Q3 2023 in Review

PEAK6 Investments sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2023, closing a stake of 1,500 shares — an estimated $32.4K sold.

PEAK6 Investments first reported a position in AMLX in Q2 2022 and held it in 2 quarters. The position peaked at $32.4K in Q2 2023. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

PEAK6 Investments reported no remaining Amylyx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 1,500 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $32.4K.
PEAK6 Investments first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 2 quarters.
PEAK6 Investments's Amylyx Pharmaceuticals position peaked at $32.4K in Q2 2023.
170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.